OLD Second National Bank of Aurora Has $2.45 Million Stake in Stryker Co. (NYSE:SYK)

OLD Second National Bank of Aurora increased its position in Stryker Co. (NYSE:SYK) by 0.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,188 shares of the medical technology company’s stock after buying an additional 75 shares during the quarter. OLD Second National Bank of Aurora’s holdings in Stryker were worth $2,452,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares during the period. Quarry LP bought a new stake in Stryker during the 1st quarter valued at approximately $27,000. Freedom Wealth Alliance LLC purchased a new position in Stryker during the 4th quarter valued at approximately $26,000. HBC Financial Services PLLC purchased a new position in shares of Stryker in the 4th quarter worth approximately $37,000. Finally, Bourgeon Capital Management LLC bought a new stake in shares of Stryker during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Stryker stock traded down $2.52 during mid-day trading on Thursday, hitting $333.51. The company’s stock had a trading volume of 469,792 shares, compared to its average volume of 1,241,465. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $126.89 billion, a P/E ratio of 40.73, a P/E/G ratio of 2.72 and a beta of 0.89. The stock’s fifty day moving average price is $350.57 and its two-hundred day moving average price is $312.03.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the company posted $3.00 EPS. The company’s quarterly revenue was up 11.8% compared to the same quarter last year. Research analysts forecast that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is currently 38.79%.

Analyst Ratings Changes

SYK has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their target price on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a research report on Wednesday, January 31st. Roth Mkm boosted their price target on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. TD Cowen upped their target price on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Finally, Royal Bank of Canada upped their price target on Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $340.45.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold 212,109 shares of company stock valued at $72,845,768 in the last quarter. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.